论文部分内容阅读
目的:探讨润肺止嗽散治疗小儿哮喘(慢性持续期)的临床效果。方法:将120例哮喘患儿分为对照组和治疗组,每组60例,对照组予儿童孟鲁司特钠(顺尔宁)治疗,治疗组予润肺止嗽散治疗,治疗3个月后,比较两组总有效率、治疗前后外周血嗜酸性粒细胞计数、夜间症状、发作频率、小儿哮喘持续时间以及住院时间。结果:治疗组总有效率显著高于对照组,差异有统计学意义(P<0.05);治疗后两组嗜酸性粒细胞总数较治疗前显著下降,且治疗组嗜酸性粒细胞计数低于对照组,差异有统计学意义(P<0.05);两组发作频率以及夜间症状评分均显著下降,且治疗组发作频率以及夜间症状评分均显著低于对照组,差异均有统计学意义(P<0.05);治疗组小儿哮喘持续时间和住院时间均显著低于对照组,差异均有统计学意义(P<0.05)。结论:润肺止嗽散治疗小儿哮喘(慢性持续期)有较好疗效,可降低外周血嗜酸性粒细胞计数,降低小儿哮喘的发作频率以及夜间的症状,缩短小儿哮喘的持续时间和住院时间。
Objective: To investigate the clinical effects of Runfei Zhisowan San on children with asthma (chronic duration). Methods: 120 asthmatic children were divided into control group and treatment group, 60 cases in each group. The control group was treated with Montelukast sodium (SD), and the treatment group was treated with Runfei Zhisuo San. Three Months later, the total effective rate, peripheral blood eosinophil count, nocturnal symptoms, seizure frequency, pediatric asthma duration and hospital stay were compared. Results: The total effective rate in the treatment group was significantly higher than that in the control group (P <0.05). The total number of eosinophils in the two groups decreased significantly after treatment, and the eosinophil count in the treatment group was lower than that in the control group (P <0.05). The frequency of seizure and nighttime symptom scores of both groups were significantly decreased, and the seizure frequency and nighttime symptom scores of the two groups were significantly lower than those of the control group (P <0.05), the difference was statistically significant (P < 0.05). The duration of pediatric asthma and hospital stay in the treatment group were significantly lower than those in the control group (P <0.05). Conclusion: Runfei Zhisowan Powder is effective in treating pediatric asthma (chronic duration), which can reduce the peripheral blood eosinophil count, reduce the frequency of asthma attacks and the symptoms at night, and shorten the duration and hospital stay of pediatric asthma .